 Biocept Inc NASDAQ:BIOC and privately held life sciences company Aegea Biotechnologies Inc have announced a supply agreement for a new PCR-based coronavirus COVID-19 assay kit designed by Aegea and co-developed by the two companies. Under the agreement, Aegea will supply the COVID-19 assay kit to Biocept for validation in its CLIA-certified, CAP-accredited high-complexity molecular lab and subsequent commercialization of a laboratory-developed test LDT. 